FDA WARNING_LETTER - Gulf Medical Fiberoptics, Inc. - May 03, 2011

The FDA issued a Warning Letter to Gulf Medical Fiberoptics, Inc. following an April 27 - May 3, 2011, inspection in Oldsmar, Florida. The firm, manufacturing endoscopic fiber optic cables and Visualux™ surgical headlights, was found to have adulterated devices under section 501(h) of the Act due to non-conformity with Quality System (QS) regulation (21 CFR Part 820) CGMP requirements. Significant violations included failures to establish and maintain adequate procedures for corrective and preventive actions (21 CFR 820.100(a)(4)), process validation (21 CFR 820.75(a)), and design validation (21 CFR 820.30(g)). The firm also failed to document acceptance activities (21 CFR 820.80(e)), establish supplier requirements (21 CFR 820.50(a)), and maintain adequate device history records (21 CFR 820.184(e)) and device master records (21 CFR 820.181). Deficiencies extended to document control (21 CFR 820.40), design input requirements (21 CFR 820.30(c)), and quality audit procedures (21 CFR 820.22). Notably, several issues were repeated from a prior FDA inspection. The firm's response was deemed largely inadequate due to insufficient documentation. Gulf Medical Fiberoptics must promptly correct all violations and submit a written response within fifteen business days, detailing specific corrective and preventive actions, supporting documentation, and a timetable. Non-compliance could lead to regulatory actions like seizure, injunction, civil money penalties, and impact product approvals and international trade. A follow-up inspection is mandated.